Table 2.
Reaction between encapsulated CA and externally added CFDA.
| [CA], μM | [CFDA], μM | Lipids | Method | rV | Note |
|---|---|---|---|---|---|
| 0.5 | 40 | POPC | M1 | 11.4 | – a |
| 1.0 | 40 | POPC | M2 | 2.0 | – b |
| 1.0 | 80 | POPC | M2 | 3.6 | – c |
| 0.5 | 40 | POPC/POPG 4/1 | M1 | 2.1 | – d |
| 0.5 | 80 | POPC/POPG 4/1 | M1 | 2.3 | – d |
| 0.5 | 160 | POPC/POPG 4/1 | M1 | 1.9 | – d |
| 0.25 | 80 | POPC/POPG 4/1 | M1 | 8.7 | – d |
| 1.0 | 80 | POPC/POPG 4/1 | M1 | 1.3 | – d |
| 1.0 | 40 | POPC/oleate 95/5 | M3 | 2.9 | – e |
| 0.25 | 40 | POPC/oleate 4/1 | M3 | 9.1 | – f |
| 0.5 | 40 | POPC/oleate 4/1 | M1 | 2.5 | – d |
a [POPC] = 0.5 mM; b [POPC] = 5 mM, pre-extruded with membranes having pores of 800 nm in diameter; c [POPC] = 2.5 mM, pre-extruded with membranes having pores of 800 nm in diameter; d 200 mM HEPES (pH 7) was used as buffer, in combination with lipid film hydration without glass beads, and [POPC] = 0.5 mM; e 5 mol% oleate helps not to forming too small vesicles; f 400 mM sodium phosphate (pH 7) was used as buffer.